Design of ongoing REMODEL trial presented at the ERA-EDTA congress 2022

Antaros Medical is proud to contribute the REMODEL trial. This multi-national study aims to evaluate the mechanism of action of GLP-1 receptor agonism by integration of magnetic resonance imaging (MRI) of kidney function and structure, and kidney biopsies. The design of the ongoing REMODEL trial is being presented at the current ERA-EDTA annual meeting in Paris #ERA22.

Find the presented abstract in the ERA-EDTA abstract book: MO399: REMODEL: A mechanistic trial evaluating the effects of semaglutide on the kidneys in people with type 2 diabetes and chronic kidney disease.
Authors: Bjornstad P, Cherney D, Lawson J, Møntegaard C, Pruijm M, Tuttle K, Vrhnjak B, Kretzler M

You can also read more about the trial on (NCT04865770): A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial).

Share on Linkedin Share on Twitter